JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

metrics 2024

Elevating ophthalmic therapies for a brighter future.

Introduction

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Metrics 2024

SCIMAGO Journal Rank0.60
Journal Impact Factor1.90
Journal Impact Factor (5 years)3.40
H-Index72
Journal IF Without Self1.90
Eigen Factor0.00
Normal Eigen Factor0.37
Influence0.76
Immediacy Index0.40
Cited Half Life8.60
Citing Half Life8.00
JCI0.84
Total Documents2113
WOS Total Citations2769
SCIMAGO Total Citations11262
SCIMAGO SELF Citations641
Scopus Journal Rank0.60
Cites / Document (2 Years)1.78
Cites / Document (3 Years)2.26
Cites / Document (4 Years)2.24

Metrics History

Rank 2024

Scopus

Ophthalmology in Medicine
Rank #31/137
Percentile 77.37
Quartile Q1
Pharmacology (medical) in Medicine
Rank #109/272
Percentile 59.93
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #163/313
Percentile 47.92
Quartile Q3

IF (Web Of Science)

OPHTHALMOLOGY
Rank 44/95
Percentile 54.20
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 231/354
Percentile 34.90
Quartile Q3

JCI (Web Of Science)

OPHTHALMOLOGY
Rank 40/95
Percentile 57.89
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 116/354
Percentile 67.23
Quartile Q2

Quartile History

Similar Journals

CURRENT PHARMACEUTICAL DESIGN

Transforming Research into Revolutionary Drug Solutions
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Journal of the Korean Ophthalmological Society

Connecting Scholars to Transform Vision Science
Publisher: KOREAN OPHTHALMOLOGICAL SOCISSN: 0378-6471Frequency: 12 issues/year

The Journal of the Korean Ophthalmological Society, with ISSN 0378-6471 and E-ISSN 2092-9374, is a pivotal resource in the field of ophthalmology, published by the esteemed Korean Ophthalmological Society. Based in South Korea, this journal is committed to advancing knowledge in ophthalmology through the dissemination of research that spans both clinical and experimental studies. Despite its current Q4 ranking in the 2023 Ophthalmology category, it serves as a crucial platform for emerging scholars, practitioners, and students seeking to contribute to and learn from the latest developments in eye care. While the journal does not currently offer open access, it is dedicated to fostering scientific dialogue and innovation within the community. With convergence years from 2018 to 2024, the journal's focus on contemporary issues in ophthalmology positions it as a relevant and timely source of information, critical for those engaged in this dynamic field. For further inquiries, the journal can be contacted at their address in Seoul, South Korea: SKY 1004 BLDG 701, 50-1 Jungnim-ro, Jung-gu, 04508.

PROGRESS IN RETINAL AND EYE RESEARCH

Advancing the Frontiers of Vision Science
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 1350-9462Frequency: 6 issues/year

PROGRESS IN RETINAL AND EYE RESEARCH, published by PERGAMON-ELSEVIER SCIENCE LTD, is a premier journal dedicated to the advancement of knowledge in the fields of ophthalmology and sensory systems. With an impressive impact factor and a Q1 category ranking in both Ophthalmology and Sensory Systems as of 2023, this journal exemplifies excellence in research dissemination. Given its stature, it ranks #1 out of 137 in Ophthalmology and #1 out of 42 in Neuroscience - Sensory Systems, placing it within the top percentile of scientific publications in these domains. The journal has been actively contributing to the field since its inception in 1994 and continues to be a vital resource for researchers, clinicians, and students seeking the latest insights and breakthroughs in the understanding of retinal diseases and eye health. While it maintains a traditional subscription model, the journal remains committed to publishing high-quality, peer-reviewed articles that drive forward the frontiers of eye research and therapeutic innovation. With its strong scientific rigor and a vast array of articles, PROGRESS IN RETINAL AND EYE RESEARCH is indispensable for anyone invested in the study of visual sciences.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Exploring the forefront of cardiovascular therapies and research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Elevating therapeutic strategies for heart health.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

International Journal of Pharmacology

Innovating Insights in Drug Development and Safety
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

Journal of Ophthalmic & Vision Research

Empowering Research in Ophthalmology
Publisher: KNOWLEDGE EISSN: 2008-2010Frequency: 4 issues/year

The Journal of Ophthalmic & Vision Research, published by KNOWLEDGE E, stands as a crucial platform for disseminating high-quality research in the field of ophthalmology. With an ISSN of 2008-2010 and an E-ISSN of 2008-322X, this journal fosters open access to valuable insights since 2010, enhancing visibility and reach for researchers globally. Based in Dubai, UAE, it has established a reputation for excellence, reflected in its Q2 ranking in Ophthalmology for 2023 and its position among the top 65th percentile in Scopus. Covering a broad spectrum of topics within ophthalmic science, the journal serves as a vital resource for professionals, researchers, and students by presenting original research, reviews, and case studies that drive innovation and collaboration within the community. As the journal continues to contribute to advancements in eye care and vision sciences, it invites scholars to explore, engage, and publish within its pages, thus enriching the global discourse on ophthalmic health.

Therapeutic Advances in Ophthalmology

Advancing ocular health through innovative research.
Publisher: SAGE PUBLICATIONS LTDISSN: 2515-8414Frequency: 1 issue/year

Therapeutic Advances in Ophthalmology is a leading open-access journal published by SAGE Publications Ltd, dedicated to advancing the understanding and treatment of ocular diseases. Since its inception in 2018, this journal has swiftly gained prominence within the ophthalmology community, proudly holding a Q1 designation in the 2023 category quartiles and ranking 34 out of 137 in the Scopus Medicine_Ophthalmology category, placing it in the top 75th percentile. By providing a platform for innovative research, clinical advancements, and educational resources, Therapeutic Advances in Ophthalmology serves as an essential resource for researchers, healthcare professionals, and students in the field. With a commitment to disseminating high-quality research accessible to all, this journal plays a critical role in shaping the future of ophthalmic care and treatment, enabling professionals to stay abreast of the latest developments and best practices in the discipline.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Elevating Clinical and Experimental Ophthalmology
Publisher: SPRINGERISSN: 0721-832XFrequency: 12 issues/year

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, published by Springer, has established itself as a premier journal in the field of ophthalmology since its inception in 1870. With an ISSN of 0721-832X and an E-ISSN of 1435-702X, this esteemed journal enjoys a notable impact in the research community, ranking Q1 in Ophthalmology and Q1 in Sensory Systems, as per the latest 2023 journal category quartiles. GRAEFES Archive is dedicated to advancing our understanding of ocular health through both clinical and experimental studies, making it an essential resource for researchers, practitioners, and students alike. Its comprehensive scope covers various aspects of ophthalmic science, reflecting its long-standing commitment to quality and excellence. Although it currently operates on a subscription basis, the journal's significant Scopus rankings—24th out of 137 in Ophthalmology—underscore its relevance and influence within the scientific community. Situated in Germany, with its address in the United States, this international journal continues to shape the discourse on vision science and therapeutic innovation.

ADVANCES IN THERAPY

Pioneering insights in medicine and pharmacology.
Publisher: SPRINGERISSN: 0741-238XFrequency: 12 issues/year

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.